1. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. (April 2023) Authors: Feagan, Brian G; Sands, Bruce E; Sandborn, William J; Germinaro, Matthew; Vetter, Marion; Shao, Jie; Sheng, Shihong; Johanns, Jewel; Panés, Julián; Tkachev, Alexander; Kalimullina, Dilara; Petryka, Robert; Osipenko, Marina; Tsarynna, Nataliia; Bilianskyi, Leonid; Kleczkowski, Dariusz; Yurkiv, And... Journal: Lancet gastroenterology and hepatology Issue: Volume 8:Number 4(2023) Page Start: 307 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Issue 10342 (11th June 2022) Authors: Sands, Bruce E; Irving, Peter M; Hoops, Timothy; Izanec, James L; Gao, Long-Long; Gasink, Christopher; Greenspan, Andrew; Allez, Matthieu; Danese, Silvio; Hanauer, Stephen B; Jairath, Vipul; Kuehbacher, Tanja; Lewis, James D; Loftus, Edward V; Mihaly, Emese; Panaccione, Remo; Scherl, Ellen; Shchu... Journal: Lancet Issue: Volume 399:Issue 10342(2022) Page Start: 2200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗